ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026

Rhea-AI Summary

ProMIS Neurosciences (Nasdaq: PMN), a clinical-stage biotechnology company focused on antibody therapeutics and vaccines for neurodegenerative diseases, will report its second quarter 2026 financial results and provide a business update on August 13, 2026.

The company will host an investor conference call and webcast on August 13, 2026 at 4:30 p.m. Eastern Time. U.S. investors can dial 1-877-407-9208, international participants can dial 1-201-493-6784, using conference ID 13761812. A replay will be available in the Investors section of the ProMIS website.

Market Context

An active S-3 shelf dated March 25, 2026 includes a $50,000,000 ATM offering and up to $200,000,000 ...

Analysis

An active S-3 shelf dated March 25, 2026 includes a $50,000,000 ATM offering and up to $200,000,000 of securities in aggregate. Low short positioning is an additional risk context.

Key Figures

Reporting date: August 13, 2026 Quarter-end date: June 30, 2026 Conference call time: 4:30 p.m. ET

3 metrics

Reporting date August 13, 2026 Second-quarter 2026 financial results and business update

Quarter-end date June 30, 2026 Second quarter 2026

Conference call time 4:30 p.m. ET August 13, 2026 investor conference call and webcast

Historical Context

5 past events · Latest: Jul 28 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 28	Interim clinical data	Positive	+23.9%	Positive blinded safety and biomarker data from the PRECISE-AD Phase 1b trial
Jul 27	Clinical data webinar	Neutral	+23.9%	Company scheduled a webinar discussing upcoming blinded interim trial data
Jul 14	Clinical data presentation	Positive	+6.7%	First human evidence of PMN310 amyloid-beta oligomer target engagement
May 28	Conference participation	Neutral	+3.8%	Company announced participation in several June healthcare and biotech conferences
May 12	Quarterly earnings report	Positive	-1.8%	Q1 results included financing proceeds, cash balance, and clinical milestones

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent clinical-related announcements were followed by positive reactions, while the prior earnings event diverged with a negative reaction.

Key Terms

toxic misfolded proteins, toxic oligomers, disease specific epitopes

3 terms

toxic misfolded proteins medical

"targeting toxic misfolded proteins in neurodegenerative diseases"

Proteins normally fold into specific shapes to do jobs in the body; toxic misfolded proteins are molecules that have taken incorrect shapes and clump or behave abnormally, damaging cells and triggering disease processes. Investors care because these misfolded proteins are often the biological cause or driver of chronic diseases, so they are major targets for drugs, diagnostics, and clinical trials—outcomes that can materially affect a company’s valuation and regulatory risk.

toxic oligomers medical

"therapeutic antibodies and vaccines selective for toxic oligomers"

Toxic oligomers are small, soluble clusters of misfolded proteins that can disrupt normal cell function and are implicated in neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Investors care because these oligomers are primary targets for new drugs and diagnostics—breakthroughs or failures in detecting or neutralizing them can significantly change a biotech company’s value, similar to how stopping a small, spreading leak can prevent a whole machine from breaking down.

disease specific epitopes medical

"targets known as Disease Specific Epitopes (DSEs)"

Disease specific epitopes are small, identifiable pieces of a pathogen or abnormal cell (like a virus, bacterium, or cancer cell) that the immune system recognizes as foreign. Think of them as unique fingerprints on a disease that immune cells or targeted therapies can latch onto; they matter to investors because drugs and diagnostics that target these specific markers can enable more precise therapies, clearer clinical trial endpoints, and differentiated products in the marketplace.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to host investor conference call and webcast at 4:30 p.m. ET.

Cambridge, Massachusetts, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced it will report financial results for the second quarter ended June 30, 2026, and provide corporate updates on August 13, 2026.

The company will host a conference call and webcast on the same day of August 13, 2026 at 4:30 p.m. ET.

Conference Call and Webcast Information: 

Date:	August 13, 2026
Time:	4:30 p.m. Eastern Time
Dial-in:	1-877-407-9208 (U.S. Investors) 1-201-493-6784 (International)
Conference I.D.:	13761812
CallMeTM:	Click Here
Webcast:	Click Here

A replay of the webcast will be available in the Investors section of the ProMIS website following the completion of the call.

About ProMIS Neurosciences Inc.
ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company's proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative diseases, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson's disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).

For further information:
Visit us at www.promisneurosciences.com

Media Contact
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com

Investor Relations Contact
Carie Pierce
VP Investor Relations & External Affairs
IR@ProMISNeurosciences.com

FAQ

When will ProMIS Neurosciences (PMN) report its Q2 2026 financial results?

ProMIS Neurosciences will report its second quarter 2026 financial results on August 13, 2026. According to ProMIS, the release will be accompanied by a corporate business update and an investor conference call and webcast held later the same day.

What time is the ProMIS Neurosciences (PMN) Q2 2026 earnings call on August 13, 2026?

The ProMIS Neurosciences Q2 2026 earnings call is at 4:30 p.m. Eastern Time on August 13, 2026. According to ProMIS, the call will include discussion of quarterly financial results and a broader corporate update for investors.

How can investors join the ProMIS Neurosciences (PMN) Q2 2026 conference call and webcast?

Investors can dial 1-877-407-9208 in the U.S. or 1-201-493-6784 internationally using conference ID 13761812. According to ProMIS, investors can also access the event via a webcast link provided for the August 13, 2026 call.

Will there be a replay of the ProMIS Neurosciences (PMN) Q2 2026 earnings webcast?

Yes, a replay of the Q2 2026 webcast will be available after the call. According to ProMIS, investors can access the replay in the Investors section of the company’s website following completion of the August 13, 2026 event.

What does ProMIS Neurosciences (PMN) develop in neurodegenerative diseases?

ProMIS Neurosciences develops therapeutic antibodies and vaccines targeting toxic misfolded protein oligomers. According to ProMIS, its EpiSelect engine identifies Disease Specific Epitopes in proteins linked to Alzheimer’s disease, ALS, FTD, multiple system atrophy, and Parkinson’s disease.

Where is ProMIS Neurosciences (PMN) headquartered and where are its offices located?

ProMIS Neurosciences has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (Canada). According to ProMIS, the company operates as a clinical-stage biotechnology firm focused on misfolded protein diseases, including several major neurodegenerative conditions.